Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curosurf in COVID-19 ARDS
NCT04502433Phase 2Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of Poractant alfa in COVID-19-associated acute respiratory distress syndrome (CARDS), sponsored by Chiesi Farmaceutici S.p.A.. Started Jan 2021; status: terminated.
02
Drugs
Poractant alfa
03
Conditions
COVID-19-associated acute respiratory distress syndrome (CARDS)
Beyond the preview
Go deeper on NCT04502433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04502433.